The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APP	ROVAL
OMB Number:	3235- 0076
Estimated burden	average
hours per response:	4.00

1. Issuer's Identity

CIK (Filer ID Number)	Previous Names	None	Entity Type
<u>0001630113</u>	METASO	LUTIONS, INC.	X Corporation
Name of Issuer	Metasoluti	ons, Inc.	Limited Partnership
BIOTRICITY INC.			Limited Liability Company
Jurisdiction of			General Partnership
Incorporation/Organization			Business Trust
NEVADA			Other (Specify)
Year of Incorporation/Organi	zation		
X Over Five Years Ago			
Within Last Five Years (Specify Y	Year)		
Yet to Be Formed			

2. Principal Place of Business and Contact Information

Name	of Issuer		
BIOTRICITY INC.			
Street	Address 1	Stı	reet Address 2
275 SHORELINE DR	VE	SUITE 150	
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
REDWOOD CITY	CALIFORNIA	94065	(416) 214-3678

3. Related Persons

Last Name	First Name	Middle Name		
Al-Siddiq	Waqaas			
Street Address 1	Street Address 2			
275 Shoreline Drive	Suite 150			
City State/Province/Country		ZIP/PostalCode		
Redwood City	CALIFORNIA	94065		

Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Ayanoglou	John	
Street Address 1	Street Address 2	
275 Shoreline Drive	Suite 150	
City	State/Province/Country	ZIP/PostalCode
Redwood City	CALIFORNIA	94065

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Health Care	Retailing
X Biotechnology	Restaurants
Health Insurance	Technology
Hospitals &	Computers
Physicians	Telecommunications
Pharmaceuticals	Other Technology
Other Health	Travel
Care	Airlines & Airports
Manufacturing	•
Real Estate	Lodging &
Commercial	Conventions
	Tourism & Travel
Construction	Services
REITS &	Other Travel
rinance	Other
	X Biotechnology Health Insurance Hospitals & Physicians Pharmaceuticals Other Health Care Manufacturing Real Estate Commercial Construction

Coal Mining	Residential	
Electric Utilities	Other Real	
Energy Conservation	Estate	
Environmental Services		
Oil & Gas		
Other Energy		

5. Issuer Size

	Revenue Range	OR	A	aggregate Net Asset Value Range
	No Revenues			No Aggregate Net Asset Value
	\$1 - \$1,000,000			\$1 - \$5,000,000
	\$1,000,001 - \$5,000,000			\$5,000,001 - \$25,000,000
	\$5,000,001 - \$25,000,000			\$25,000,001 - \$50,000,000
	\$25,000,001 - \$100,000,000			\$50,000,001 - \$100,000,000
	Over \$100,000,000			Over \$100,000,000
X	Decline to Disclose			Decline to Disclose
	Not Applicable			Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Investment Company Act Section 3(c)				
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1)	Section 3(c)(9)			
Rule 504 (b)(1)(i)	Section 3(c)(2)	Section 3(c)(10)			
Rule 504 (b)(1)(ii)	Section 3(c)(3)	Section 3(c)(11)			
Rule 504 (b)(1)(iii)	Section 3(c)(4)	Section 3(c)(12)			
X Rule 506(b) Rule 506(c)	Section 3(c)(5)	Section 3(c)(13)			
Securities Act Section 4(a)(5)	Section 3(c)(6)	Section 3(c)(14)			
	Section 3(c)(7)				

7. Type of Filing

X	New Notice	Date of First Sale	2019-12-19	First Sale Yet to Occur
	Amendment			

8. Duration of Offering

Does the Issuer intend this offering to last more than one year?	Yes X No
--	----------

9. Type(s) of Securities Offered (select all that apply)

X	Equity	Pooled Investment Fund Interests
	Debt	Tenant-in-Common Securities
	Option, Warrant or Other Right to Acquire Another Security	Mineral Property Securities
	Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security	Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination	Yes X No
transaction, such as a merger, acquisition or exchange offer?	1 CS X IVO

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

12. Sales Compensation

Recipient		Recipient CRD Number X None	
(Associated) Broker or Dealer X None		(Associated) Broker or Dealer CRD X None	
Street Address 1		Street Address 2	
City		State/Province/Country	ZIP/Postal Code
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	All States	Foreign/non-US	

13. Offering and Sales Amounts

Total Offering Amount	\$10,000,000	USD	or	Indefinite
Total Amount Sold	\$6,000,000	USD		
Total Remaining to be Sold	\$4,000,000	USD	or	Indefinite

Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.	
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:	1

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$0 US	D Estimate
Finders' Fees	\$0 US	D Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

|--|

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
BIOTRICITY INC.	/s/ John Ayanoglou	John Ayanoglou	Chief Financial Officer	2019-12-31

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their antifraud authority.